{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"9"}],"units":"Participants"}],"description":"Number (percentage) of patients experiencing at least one treatment-emergent adverse event, defined as those untoward medical events with onset after the first dose of study drug or existing events that worsened after the first dose during the study","groups":[{"description":"VRx-3996: 10 mg twice daily (BID) valganciclovir: 900 mg BID","id":"OG000","title":"Phase 1b Dose Escalation Cohort 1"},{"description":"VRx-3996: 5 mg BID valganciclovir: 450 mg BID","id":"OG001","title":"Phase 1b Dose Escalation Cohort 2a"},{"description":"VRx-3996: 10 mg once daily (QD) valganciclovir: 450 mg BID","id":"OG002","title":"Phase 1b Dose Escalation Cohort 2b"},{"description":"VRx-3996: 10 mg QD valganciclovir: 900 mg QD","id":"OG003","title":"Phase 1b Dose Escalation Cohort 2c"},{"description":"VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD","id":"OG004","title":"Phase 1b Dose Escalation Cohort 3"},{"description":"VRx-3996 (RP2D: 20 mg QD on Days 1 to 4/week) and valganciclovir (RP2D: 900 mg QD)","id":"OG005","title":"Phase 2 Dose Expansion - Capsule"},{"description":"VRx-3996 (RP2D: 20 mg QD on Days 1 to 4/week) and valganciclovir (RP2D: 900 mg QD)","id":"OG006","title":"Phase 2 Dose Expansion - Tablet"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set, defined as all enrolled patients who received at least 1 dose of study treatment. Valganciclovir dosage reductions were allowed for participants with renal impairment at study entry or during study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years","title":"Number (Proportion) of Participants With Adverse Events (AEs)","type":"PRIMARY","unitOfMeasure":"Participants"}